The federal government has made huge progress in lowering regulatory barriers in order to accelerate access to health care during the coronavirus crisis, including allowing patients to talk with their doctors by telemedicine visits. But one group of particularly vulnerable patients has been left out: Medicare beneficiaries needing access to infused or injected drugs that generally must be administered by clinicians in doctors’ offices or hospitals.